These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2402789)

  • 21. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis.
    Rolstad B; Benestad HB
    Immunology; 1991 Sep; 74(1):86-93. PubMed ID: 1937576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transforming growth factor-beta inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras.
    Billiau AD; Sefrioui H; Overbergh L; Rutgeerts O; Goebels J; Mathieu C; Waer M
    Transplantation; 2001 Jan; 71(2):292-9. PubMed ID: 11213076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation.
    Salam A; Waer M
    Transplantation; 1996 Mar; 61(5):826-30. PubMed ID: 8607190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of total lymphoid irradiation on natural killer cells and cytotoxic and primed T lymphocytes.
    Weiss L; Slavin S
    Isr J Med Sci; 1994 Apr; 30(4):253-9. PubMed ID: 8175324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J; Gulati SC
    Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection.
    Corado J; Toro F; Rivera H; Bianco NE; Deibis L; De Sanctis JB
    Clin Exp Immunol; 1997 Sep; 109(3):451-7. PubMed ID: 9328121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells.
    Sykes M; Abraham VS
    Transplantation; 1992 May; 53(5):1063-70. PubMed ID: 1533968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).
    Kedar E; Or R; Naparstek E; Zeira E; Slavin S
    Bone Marrow Transplant; 1988 Mar; 3(2):129-40. PubMed ID: 3048477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific recognition of human leukemic cells by allogeneic T cell lines.
    Sosman JA; Oettel KR; Hank JA; Fisch P; Sondel PM
    Transplantation; 1989 Sep; 48(3):486-95. PubMed ID: 2571206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: participation of both T cells and NK cells in the killing.
    Parajuli P; Nishioka Y; Nishimura N; Singh SM; Hanibuchi M; Nokihara H; Yanagawa H; Sone S
    J Leukoc Biol; 1999 Jun; 65(6):764-70. PubMed ID: 10380897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow.
    Soiffer RJ; Mauch P; Tarbell NJ; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Murrey CI; Coral F; Bosserman L
    Bone Marrow Transplant; 1991 Jan; 7(1):23-33. PubMed ID: 2043874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ; Silver HK; Kong S
    Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of postbinding target cell lysis and of lymphokine-induced enhancement of human natural killer cell activity by in vitro exposure to ultraviolet B radiation.
    Elmets CA; Larson K; Urda GA; Schacter B
    Cell Immunol; 1987 Jan; 104(1):47-58. PubMed ID: 3802213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.